[1] Researchers at the University of Zürich, Switzerland formed Molecular Partners AG in 2004 while studying monoclonal antibodies.

[3] Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN).

[3] DARPins constitute a new class of potent, specific and versatile small-protein therapies, and are used as investigational tools in various therapeutic and diagnostic applications.

This approach enables the design of medicines that can inhibit multiple disease-specific targets and may improve outcomes for patients living with cancer, ophthalmic diseases and other disorders.

[9] In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.